# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mustang Bio announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stoc...
-SEC Filing
- SEC Filing
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy ...
Financial Results: As of December 31, 2023, Mustang's cash and cash equivalents and restricted cash totaled $7.0 million...